Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió acceptadaData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/126377
A Photoswitchable Antimetabolite for Targeted Photoactivated Chemotherapy
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
The efficacy and tolerability of systemically administered anticancer agents are limited by their off-target effects. Precise spatiotemporal control over their cytotoxic activity would allow improving chemotherapy treatments, and light-regulated drugs are well suited to this purpose. We have developed phototrexate, the first photoswitchable inhibitor of the human dihydrofolate reductase (DHFR), as a photochromic analogue of methotrexate, a widely prescribed chemotherapeutic drug to treat cancer and psoriasis. Quantification of the light-regulated DHFR enzymatic activity, cell proliferation, and in vivo effects in zebrafish show that phototrexate behaves as a potent antifolate in its photoactivated cis configuration and that it is nearly inactive in its dark-relaxed trans form. Thus, phototrexate constitutes a proof-of-concept to design light-regulated cytotoxic small molecules and a step forward to develop targeted anticancer photochemotherapies with localized efficacy and reduced adverse effects
Matèries (anglès)
Citació
Citació
MATERA, Carlo, GOMILA JUANEDA, Alexandre, CAMARERO, Núria, LIBERGOLI, Michela, SOLER PRAT, Concepció, GOROSTIZA LANGA, Pablo ignacio. A Photoswitchable Antimetabolite for Targeted Photoactivated Chemotherapy. _Journal of the American Chemical Society_. 2018. Vol. 140, núm. 46, pàgs. 15764-15773. [consulta: 23 de gener de 2026]. ISSN: 0002-7863. [Disponible a: https://hdl.handle.net/2445/126377]